Skip to results
Modify your search
NARROW
1-20 of 351
Section: Clinical Trial Results
Journal Article
A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC
The Oncologist, Volume 30, Issue 4, April 2025, oyaf053, https://doi.org/10.1093/oncolo/oyaf053
Published: 11 April 2025
Journal Article
Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection Get access
The Oncologist, Volume 30, Issue 3, March 2025, oyaf006, https://doi.org/10.1093/oncolo/oyaf006
Published: 29 March 2025
Journal Article
Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma
The Oncologist, Volume 30, Issue 3, March 2025, oyae203, https://doi.org/10.1093/oncolo/oyae203
Published: 28 March 2025
Journal Article
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies
The Oncologist, Volume 30, Issue 3, March 2025, oyaf032, https://doi.org/10.1093/oncolo/oyaf032
Published: 26 March 2025
Journal Article
A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling
The Oncologist, oyae339, https://doi.org/10.1093/oncolo/oyae339
Published: 25 December 2024
Journal Article
Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer
The Oncologist, Volume 30, Issue 1, January 2025, oyae200, https://doi.org/10.1093/oncolo/oyae200
Published: 02 December 2024
Journal Article
Pegylated liposomal doxorubicin in partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer: a prospective study
The Oncologist, Volume 30, Issue 1, January 2025, oyae194, https://doi.org/10.1093/oncolo/oyae194
Published: 04 November 2024
Journal Article
Hand therapy interventions for the prevention of chemotherapy-induced peripheral neuropathy of the hands in patients with pancreatic cancer
The Oncologist, Volume 29, Issue 12, December 2024, Pages 1095–e1778, https://doi.org/10.1093/oncolo/oyae285
Published: 22 October 2024
Journal Article
Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer: a prospective study
The Oncologist, Volume 30, Issue 2, February 2025, oyae223, https://doi.org/10.1093/oncolo/oyae223
Published: 11 September 2024
Journal Article
Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma
The Oncologist, Volume 29, Issue 11, November 2024, Pages 997–e1614, https://doi.org/10.1093/oncolo/oyae207
Published: 03 September 2024
Journal Article
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
The Oncologist, Volume 29, Issue 10, October 2024, Pages e1406–e1418, https://doi.org/10.1093/oncolo/oyae171
Published: 11 July 2024
Journal Article
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study
The Oncologist, Volume 29, Issue 10, October 2024, Pages e1396–e1405, https://doi.org/10.1093/oncolo/oyae109
Published: 21 June 2024
Journal Article
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G
The Oncologist, Volume 29, Issue 8, August 2024, Pages 723–e1093, https://doi.org/10.1093/oncolo/oyae119
Published: 14 June 2024
Journal Article
A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors
The Oncologist, Volume 29, Issue 8, August 2024, Pages 721–e1088, https://doi.org/10.1093/oncolo/oyae117
Published: 01 June 2024
Journal Article
Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget’s disease (EMPD-HER2DOC)
The Oncologist, Volume 29, Issue 9, September 2024, Pages e1201–e1208, https://doi.org/10.1093/oncolo/oyae097
Published: 01 June 2024
Journal Article
Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results
The Oncologist, Volume 29, Issue 9, September 2024, Pages 819–e1223, https://doi.org/10.1093/oncolo/oyae108
Published: 31 May 2024
Journal Article
Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors
The Oncologist, Volume 29, Issue 9, September 2024, Pages 817–e1213, https://doi.org/10.1093/oncolo/oyae118
Published: 31 May 2024
Journal Article
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
The Oncologist, Volume 29, Issue 7, July 2024, Pages 638–e952, https://doi.org/10.1093/oncolo/oyae096
Published: 30 May 2024
Journal Article
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating “BRCAness” Genotype (ROAR)
The Oncologist, Volume 29, Issue 5, May 2024, Pages 450–e725, https://doi.org/10.1093/oncolo/oyae030
Published: 07 March 2024
Journal Article
Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study
The Oncologist, Volume 29, Issue 4, April 2024, Pages 364–e578, https://doi.org/10.1093/oncolo/oyae005
Published: 16 February 2024
